Form 4: Contineum Therapeutics Director Olivia Ware Granted 14,750 Stock Options Under Compensation Plan

Contineum Therapeutics, Inc. Director Olivia Ware was granted 14,750 stock options at an exercise price of $4.01, vesting over one year or until the next annual meeting, as part of the company's non-employee director compensation program.

Summary

• Olivia C. Ware, a Director of Contineum Therapeutics, Inc. (CTNM), was granted 14,750 stock options.
• The options have an exercise price of $4.01 per share.
• The grant date and exercisable date is June 26, 2025, with an expiration date of June 25, 2035.
• These options were granted under the Issuer's 2024 Equity Incentive Plan and are part of the Non-Employee Director Compensation Program.
• The program stipulates that each non-employee director who continues to serve after the annual meeting automatically receives 14,750 stock options.
• The options will vest in full on the earlier of June 26, 2026 (one-year anniversary of the grant date) or the next regular annual meeting of stockholders, contingent on Ms. Ware's continuous service.
• Following this transaction, Ms. Ware beneficially owns 14,750 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director as part of a pre-established compensation plan, which is a standard practice to align director and shareholder interests. It indicates stable corporate governance and continued director commitment.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the stock price increases.
• It reflects a standard, pre-approved compensation structure for non-employee directors, indicating consistent corporate governance practices.
• The director's continued service implies ongoing commitment to the company's oversight and strategic direction.

Risks

• The value of the stock options is subject to the future performance of Contineum Therapeutics, Inc.'s stock price. If the stock price does not exceed the exercise price of $4.01, the options may expire worthless.
• Vesting of the options is contingent upon the director's continuous service, meaning the options could be forfeited if service ceases before the vesting conditions are met.

Future Outlook

The stock options granted to Director Olivia Ware are set to vest in full on the earlier of June 26, 2026, or the next regular annual meeting of stockholders, contingent upon her continuous service. This indicates a future milestone for the director's compensation and continued alignment with company performance.

Management Comments

• "Options granted under the Issuer's 2024 Equity Incentive Plan (the 'Plan'), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock."

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, including the pharmaceutical/biotechnology sector (given 'Therapeutics' in the company name). This practice aims to align the interests of the board members with those of the shareholders by providing an incentive tied to the company's stock performance. The specific number of options and vesting schedule are typically determined by the company's compensation committee based on industry benchmarks and the director's role.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice in publicly traded companies, particularly within the life sciences and technology sectors, to align director incentives with shareholder value.
• The vesting schedule, which includes a one-year anniversary or the next annual meeting, is a common approach to ensure continued service and commitment from board members.
• The specific number of shares (14,750) and exercise price ($4.01) would typically be benchmarked against peer companies of similar market capitalization and stage of development, though specific comparable companies are not mentioned in this filing. For example, companies like BioNTech SE or Moderna Inc. often use equity grants as a significant component of director compensation, though the scale would differ based on company size.

Corporate Governance

Related Party Transactions

• The grant of stock options to Olivia C. Ware, a director, constitutes a related party transaction, as it involves compensation provided by the company to a member of its board. However, it is a standard and disclosed form of compensation under a pre-approved program.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with those of shareholders, as the options' value is tied to the company's stock performance. It represents a cost of governance but is intended to incentivize long-term value creation.
• Director (Olivia C. Ware): Receives a significant equity incentive, contingent on continued service and company performance, enhancing her personal stake in the company's success.

Next Steps

• The stock options granted to Olivia C. Ware will vest in full on the earlier of June 26, 2026, or the next regular annual meeting of stockholders, subject to her continuous service.

Key Dates

Keywords

Contineum Therapeutics, CTNM, SEC Form 4, Stock Option Grant, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Insider Transaction, Corporate Governance, Executive Compensation, Public Company Filing